SCHEMBL5415077

SCHEMBL5415077

CC(C)Cn1c(=O)n(C)c(=O)c2c(-c3cccn3C)n(Cc3cn(Cc4ccccc4)c4ccccc34)nc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 6/20 0.46
PDE1B Q01064 6/20 0.46
PDE1C Q14123 6/20 0.46
PDE2A O00408 4/20 0.45
PDE4A P27815 3/20 0.39
PDE4B Q07343 3/20 0.39
PDE4C Q08493 3/20 0.39
PDE4D Q08499 3/20 0.39
PDE3B Q13370 3/20 0.39
PDE3A Q14432 3/20 0.39
CHRM1 P11229 1/20 0.39
SLC16A1 P53985 1/20 0.39
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5411147 0.86 PDE1A (0.46) PDE1APDE1BPDE1CPDE2APDE4A
SCHEMBL5407568 0.84 PDE1A (0.46) PDE1APDE1BPDE1CPDE2APDE4A
SCHEMBL5402601 0.82 SLC16A1 (0.53) PDE1APDE1BPDE1CPDE3BPDE3A
SCHEMBL5411378 0.82 TP53 (0.45) PDE1APDE1BPDE1CPDE2AKDM4E
SCHEMBL5407500 0.82 SLC16A1 (0.45) SLC16A1
SCHEMBL5404342 0.80 PDE1A (0.38) PDE1APDE1BPDE1CPDE2APDE3B
SCHEMBL5407470 0.80 PDE1A (0.42) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL5417927 0.79 PDE1A (0.40) PDE1APDE1BPDE1CPDE2APDE4A
SCHEMBL5407589 0.77 PDE1A (0.38) PDE1APDE1BPDE1CPDE2AKMT2A
SCHEMBL5407922 0.77 SLC16A1 (0.41) PDE1APDE1BPDE1CPDE2ASLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285558-B2 Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections ASTRAZENECA AB (SE) 2007-10-23 US disclosed
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections ASTRAZENECA AB (SE) 2004-12-16 US disclosed
EP-1412355-A1 NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2003002567-A1 NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS ASTRAZENECA AB (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections DPYD, HPGDS, PGC PDE1A 4056/4885PDE1B 4206/4885PDE1C 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.